Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL

Acute myeloid leukemia (AML) and B-cell acute lymphocytic leukemia (B-ALL) are severe blood malignancies affecting both adults and children. Chimeric antigen receptor (CAR)-based immunotherapies have proven highly efficacious in the treatment of leukemia. However, the challenge of the immune escape...

Full description

Bibliographic Details
Main Authors: Guillermo Ureña-Bailén, Jérôme-Maurice Dobrowolski, Yujuan Hou, Alicia Dirlam, Alicia Roig-Merino, Sabine Schleicher, Daniel Atar, Christian Seitz, Judith Feucht, Justin S. Antony, Tahereh Mohammadian Gol, Rupert Handgretinger, Markus Mezger
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:International Journal of Molecular Sciences
Subjects:
NK-92
CD19-CAR
CD276-CAR
leukemia
AML
B-ALL
Online Access:https://www.mdpi.com/1422-0067/23/21/12828

Internet

https://www.mdpi.com/1422-0067/23/21/12828

Similar Items